Manch-based Boston Therapeutics closes $5.3M placement of common stock, warrants
Proceeds of the offering will be used to fund additional clinical trials for PAZ320, a non-systemic chewable drug designed to reduce the elevation of postprandial glucose or post-meal blood sugar for treatment of patients with Type 2 diabetes, and for general corporate purposes.
LATEST NEW HAMPSHIRE ANGLE
Mark Hayward's City Matters: Dean Kamen is a genius inventor, and he's pretty good at oratory, too
NH couple hit slot for $2.4m in Las Vegas